-
Mashup Score: 8
Pivekimab sunirine showed single-agent activity across multiple doses, with a recommended phase 2 dose of 0·045 mg/kg once every 3 weeks. These findings led to a phase 1b/2 study of pivekimab sunirine plus azacitidine and venetoclax in patients with CD123-positive acute myeloid leukaemia.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8Unpacking the Significance of Liso-Cel’s FDA Approval and Continued Investigation in CLL/SLL - 1 month(s) ago
Saad J. Kenderian, MB, CHB, expands on the significance of liso-cel’s approval in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 68Novel Biomarkers and Molecular Targets in ALL - 1 month(s) ago
Current Hematologic Malignancy Reports – Acute lymphoblastic leukemia (ALL) is a widely heterogeneous disease in terms of genomic alterations, treatment options, and prognosis. While ALL is…
Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Dr Jabbour on the Significance of the FDA Approval of Ponatinib Plus Chemo for PH+ ALL - 1 month(s) ago
Elias Jabbour, MD, discusses the FDA approval of ponatinib plus chemotherapy for Philadelphia chromosome–positive acute lymphoblastic leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4FDA Approves Iclusig Plus Chemo for Ph+ ALL - 1 month(s) ago
The Food and Drug Administration granted an accelerated approval to Iclusig, described as the new “standard of care” for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 0Venetoclax Displays Durable Efficacy in Relapsed/Refractory CLL - 1 month(s) ago
Patients with relapsed/refractory chronic lymphocytic leukemia experienced long-lasting responses with venetoclax.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Venetoclax Displays Durable Efficacy in Relapsed/Refractory CLL - 1 month(s) ago
Patients with relapsed/refractory chronic lymphocytic leukemia experienced long-lasting responses with venetoclax.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0TERN-701 Receives FDA Orphan Drug Designation in CML - 1 month(s) ago
TERN-701 has received orphan drug designation from the FDA for the treatment of patients with chronic myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 156ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia - 1 month(s) ago
The following ESMO Clinical Practice Guideline (CPG) has been recently updated with new treatment recommendations:
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study - 1 month(s) ago
Pivekimab sunirine showed single-agent activity across multiple doses, with a recommended phase 2 dose of 0·045 mg/kg once every 3 weeks. These findings led to a phase 1b/2 study of pivekimab sunirine plus azacitidine and venetoclax in patients with CD123-positive acute myeloid leukaemia.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
NEW A phase 1/2 trial of pivekimab sunirine (IMGN632), a first-in-class antibody–drug conjugate comprising a high-affinity CD123 antibody, cleavable linker, and novel indolinobenzodiazepine pseudodimer payload, in patients with R/R AML. #leusm https://t.co/YVImnuf8lK https://t.co/8NGn8CZCK0